Lixte Biotechnology (NASDAQ:NMAD) Stock: Insider John Francis Travaglini Purchases 5,000 Shares

Lixte Biotechnology Holdings, Inc. (NASDAQ:NMAD – Get Free Report) Director John Francis Travaglini acquired 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 18th. The shares were acquired at an average cost of $2.85 per share, for a total transaction of $14,250.00. Following the completion of the transaction, the director directly owned 5,000 shares of the company’s stock, valued at $14,250. The trade was a ? increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link.

Lixte Biotechnology Stock Performance

NASDAQ NMAD opened at $2.56 on Friday. Lixte Biotechnology Holdings, Inc. has a one year low of $2.13 and a one year high of $8.38. The stock has a 50-day moving average of $3.65 and a 200 day moving average of $4.64. The company has a market capitalization of $41.22 million, a price-to-earnings ratio of -1.82 and a beta of 1.37.

Lixte Biotechnology (NASDAQ:NMAD – Get Free Report) last issued its earnings results on Monday, November 16th. The company reported ($0.74) earnings per share for the quarter. The business had revenue of $0.47 million during the quarter.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on NMAD. Wall Street Zen lowered shares of Lixte Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, August 22nd. Weiss Ratings upgraded shares of Lixte Biotechnology from a “sell (e)” rating to a “sell (d)” rating in a research report on Friday, September 25th. One analyst has rated the stock with a Sell rating. According to MarketBeat, the company has an average rating of “Sell”.

Read Our Latest Stock Analysis on Lixte Biotechnology

Institutional Trading of Lixte Biotechnology

A number of hedge funds have recently bought and sold shares of the company. Equitable Holdings Inc. bought a new position in Lixte Biotechnology in the second quarter valued at about $74,000. FNY Investment Advisers LLC purchased a new position in Lixte Biotechnology in the second quarter worth about $330,000. BlackRock Inc. bought a new stake in shares of Lixte Biotechnology during the 2nd quarter valued at about $564,000. Finally, Legacy Wealth Managment LLC ID bought a new stake in shares of Lixte Biotechnology during the 2nd quarter valued at about $4,457,000. Hedge funds and other institutional investors own 5.10% of the company’s stock.

Lixte Biotechnology Company Profile

(Get Free Report)

Lixte Biotechnology Holdings is a clinical-stage biotechnology company focused on developing treatments for cancer. Its research centers on compounds that target protein phosphatase 2A (PP2A), an enzyme involved in cellular processes that can influence cancer growth and treatment response. The company’s lead investigational candidate, LB-100, is a small-molecule PP2A inhibitor being studied for potential use alongside existing cancer treatments. Lixte has described its approach as aiming to make tumors more responsive to therapies such as chemotherapy and immunotherapy.

Featured Articles

Receive News & Ratings for Lixte Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lixte Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.